Brief: Oncodesign H1 Net Loss Stands At Eur 3.9 Mln

Oncodesign Precision Medicine Opm SA

19/09/2023 19:11

Sept 19 (Reuters) - Oncodesign Precision Medicine Opm SA
 ALOPM.PA :
    * NET LOSS OF EUR 3.9 MILLION DUE TO ITS RESEARCH AND
DEVELOPMENT
EXPENSES OF EUR 5 M IN FIRST HALF OF 2023
    * H1 CASH POSITION OF EUR 9.5M TO ENSURE DEVELOPMENT OF ITS
PROGRAMS WITH FINANCIAL VISIBILITY INCREASED BY 4 MONTHS
    * REVENUES AND OPERATING INCOME OF EUR 1.1 M FOR FIRST HALF
OF
2023, +121% VERSUS. LAST YEAR

Source text for Eikon:  ID:nBwb0ZbZHa 
Further company coverage:  ALOPM.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))